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ABSTRACT
This study investigates the influence expression of the MYCN oncogene has 
on the DNA damage response, replication fork progression and sensitivity to 
PARP inhibition in neuroblastoma. In a panel of neuroblastoma cell lines, MYCN 
amplification or MYCN expression resulted in increased cell death in response to a 
range of PARP inhibitors (niraparib, veliparib, talazoparib and olaparib) compared 
to the response seen in non-expressing/amplified cells. MYCN expression slowed 
replication fork speed and increased replication fork stalling, an effect that was 
amplified by PARP inhibition or PARP1 depletion. Increased DNA damage seen was 
specifically induced in S-phase cells. Importantly, PARP inhibition caused a significant 
increase in the survival of mice bearing MYCN expressing tumours in a transgenic 
murine model of MYCN expressing neuroblastoma. Olaparib also sensitized MYCN 
expressing cells to camptothecin- and temozolomide-induced cell death to a greater 
degree than non-expressing cells. In summary, MYCN expression leads to increased 
replication stress in neuroblastoma cells. This effect is exaggerated by inhibition of 
PARP, resulting in S-phase specific DNA damage and ultimately increased tumour 
cell death. PARP inhibition alone or in combination with classical chemotherapeutics 
is therefore a potential therapeutic strategy for neuroblastoma and may be more 
effective in MYCN expressing tumours.
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INTRODUCTION
Neuroblastoma (NB), a tumour derived from 
primitive neural crest cells in the sympathetic nervous 
system, is the most common extracranial solid 
childhood tumour [1, 2]. Patients with NB are stratified 
into risk groups depending on a number of features, 
including age at diagnosis, stage, MYCN amplification 
status and DNA ploidy [3]. At the time of diagnosis, 
the majority of patients have high-risk disease, defined 
as the presence of stage IV disease or amplification of 
the MYCN oncogene. MYCN amplification is present 
in 25% of NB patients and strongly predicts poor 
prognosis independently of other factors [4, 5]. The 
majority of patients with amplification also display 
high MYCN expression. With recent intensification 
of treatment, survival in MYCN amplified patients has 
improved so that outcomes are now comparable with 
other high-risk patients. However, approximately half 
of children with high-risk NB still relapse and die of 
their disease despite intensive therapies including 
multi-agent induction chemotherapy, surgery, 
radiotherapy, high-dose chemotherapy with autologous 
stem cell transplant, differentiation therapy and anti 
GD2 immunotherapy. We are now at the stage where 
conventional therapy is at the limits of tolerability and 
hence novel therapies targeting the molecular drivers of 
NB are urgently needed. As a driver of neuroblastoma, 
associated with poor outcome, MYCN is an important 
potential therapeutic target for high-risk NB. Whilst it 
seems intuitive to target MYCN directly, this has proved 
technically difficult [6]. Increased understanding of 
MYCN biology is needed in order that alternative ways 
to exploit MYCN expression can be explored.
Poly(ADP-ribose) polymerase (PARP) enzymes 
PARP1, PARP2 and PARP3 bind to, and are activated at, 
sites of DNA damage. Here they synthesise poly(ADP-
ribose) (PAR) chains on acceptor proteins as well as 
themselves [7, 8]. The PAR signal then recruits repair 
factors to the damage, including PARP proteins that play a 
key role in coordinating the repair of single strand [9–16] 
and double strand DNA breaks [17–20] and in the restart 
of stalled or collapsed DNA replication forks [21–23]. 
PARP inhibitors, targeting PARPs 1, 2 and 3 to various 
degrees, are considered an exciting prospect for treatment 
of cancers with particular genetic alterations [24]. Several 
are approved for use in BRCA-defective high-grade serous 
ovarian cancer and in BRCA1/2 mutant HER2 negative 
breast cancers, while multiple trials in other homologous 
recombination deficient tumour types are still ongoing. 
In addition, PARP inhibitors effectively sensitize tumour 
cells to other DNA damaging agents. Recently it has 
been shown that NB cells with MYCN expression have 
higher levels of PARP1/2 and that at relatively high 
concentrations the PARP inhibitor olaparib can selectively 
kill NB cell lines expressing MYCN [25]. It is purported 
that this is because PARP inhibitors induce high levels 
of replication stress in MYCN expressing tumours. 
However, other reports do not confirm sensitivity to PARP 
inhibitors despite seeing significant alterations in levels of 
replication stress [26, 27].
Here we show directly that expression of the 
oncogene MYCN induces collapse of replication forks 
and sensitivity to the PARP inhibitors olaparib, niraparib 
and veliparib in a number of MYCN-amplified and 
expressing NB tumour cell lines, causing replication 
stress and increased DNA damage in S and G2/M cells. 
Significantly, we also demonstrate for the first time 
that treatment with olaparib (a PARP1/2/3 inhibitor) 
moderately increases survival in a transgenic murine 
model of MYCN expressing NB. Our work provides 
mechanistic insight into the relationship between PARP 
and MYCN and adds to the growing evidence that PARP 
inhibitors may have therapeutic potential in the treatment 
of MYCN expressing NB.
RESULTS
MYCN expression increases the sensitivity of NB 
cells to PARP inhibition
Previous reports regarding the role of MYCN in the 
response to PARP inhibitors are contradictory [25–27]. 
Furthermore when MYCN dependent sensitivity has 
been seen it was reported as specific to PARP inhibitors 
that induce high levels of PARP trapping on DNA (i.e., 
olaparib and talazoparib but not veliparib after 48 h 
incubation [25]). Here, a panel of MYCN-amplified/
expressing and non-amplified/expressing NB tumour 
cell lines were screened for reduced viability in the 
presence of the PARP inhibitors olaparib (AZD-2281) 
and niraparib (MK-4827) (Figure 1A and Supplementary 
Figure 1). The MYCN expressing cell lines (Kelly, IMR5, 
SHEP-Tet21N - MYCN ON) displayed significantly 
lower GI50 values than the non-expressing ones (SHEP-
1, SKNSH, SHEP-Tet21N+DOX - MYCN OFF, SKNAS) 
(Figure 1B, Student’s t-test p<0.05 for both inhibitors). 
In addition, there appears to be a relationship between 
the degree of MYCN expression and sensitivity to PARP 
inhibition, with SHEP-Tet21/N cells having intermediate 
expression of MYCN and moderate GI50 values. These 
data therefore support a role for MYCN in influencing 
the response to PARP inhibition. Although the PARP 
inhibitor niraparib is reported as having slightly greater 
trapping ability than olaparib, both result in greater than 
five fold higher trapping than the PARP inhibitor veliparib 
(ABT-888) [28] and each has moderate trapping when 
compared to the second generation clinical PARP inhibitor 
talazoparib (BMN-673) [28, 29]. To examine further the 
ability of MYCN expression to influence sensitivity to 
PARP inhibition and to test the influence of trapping, 
the cytotoxicity of three PARP inhibitors, talazoparib, 
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olaparib and veliparib, was compared by MTT assay in 
the NB cell lines, IMR-32 (MYCN-amplified) and SHEP-
1 (non-MYCN-amplified). Inhibition of PARP activity 
was confirmed in each cell line using immunofluorescent 
staining (Figure 1D and Supplementary Figure 2). After 
96 hours drug exposure, across a range of concentrations 
of each PARP inhibitor, the MYCN-amplified IMR-32 
cells showed significantly reduced viability compared 
to non-amplified SHEP-1 cells (Figure 1E, Student’s 
t-test p<0.01 at the highest concentrations tested). This 
suggests that MYCN expression can influence response 
to a range of PARP inhibitors regardless of the degree of 
trapping. However, the potency of talazoparib was far 
greater in both MYCN-amplified and non-amplified cells. 
This could be due to differences in the IC50 values of 
each inhibitor [30–32], and/or because the degree of PARP 
trapping likely influences the sensitivity of NB cell lines to 
PARP inhibitors regardless of MYCN expression. Relative 
protein levels of MYCN in each cell line are shown in 
Figure 1C.
The MTT assay estimates cell viability. In order to 
assess cell survival following PARP inhibition clonogenic 
survival assays were undertaken, and to clarify the role of 
MYCN an isogenic model of the MYCN tet-repressible 
cell line, SHEP-Tet21/N was used [33]. MYCN expression 
was repressed for 48 h prior to continuous exposure to 
the PARP inhibitors olaparib, talazoparib or veliparib 
(Supplementary Figure 3). In this model MYCN 
expressing cells (MYCN ON) displayed significantly 
reduced cell survival compared to non-expressing (MYCN 
OFF) cells with each of the PARP inhibitors (Figure 
2A and Supplementary Figure 3, Student’s t-test p<0.001 
at 5 μM olaparib, p<0.01 at 5 nM talazoparib and p<0.05 
at 5 μM veliparib). As with the cell viability assays, 
talazoparib was the most potent inhibitor regardless of 
MYCN expression, however, for each inhibitor the LD50 
was approximately 3× higher in MYCN OFF than MYCN 
OFF cells (Figure 2E), suggesting that in this context 
trapping may not be the main factor driving cytotoxicity. 
The PARP inhibitor olaparib is used for the rest of this 
study. Adding tetracycline to the parental SHEP-1 cells did 
not affect cell survival in olaparib confirming the effect is 
due to expression of MYCN rather than off target effects 
of tetracycline (Supplementary Figure 4A). Inhibition 
of PARP activity was confirmed by immunofluorescent 
staining and western blotting and MYCN expression was 
confirmed by western blotting (Figure 2B and 2C and 
Supplementary Figure 5). To further demonstrate that 
MYCN can affect sensitivity to olaparib, MYCN was 
knocked down in MYCN-amplified IMR-32 cells using 
two different siRNAs and sensitivity to olaparib was tested 
by clonogenic survival (Figure 2D). Reduction of MYCN 
protein level significantly reduced sensitivity to olaparib 
with a 2.4–3.5 fold increase in cell survival at 2.5 μM 
(Student’s t-test p<0.05 and <0.001 for MYCN siRNA-B 
and -C, respectively). Neither Ki67 staining or sensitivity 
to the cytotoxic agent etoposide were altered between 
MYCN depleted and control IMR-32 cells, demonstrating 
that the PARP inhibitor resistance induced is not simply a 
function of reduced proliferative fraction in the setting of 
reduced MYCN protein levels (Supplementary Figure 4B). 
Taken together these data strongly support the hypothesis 
that the presence of MYCN protein results in increased 
sensitivity to PARP inhibitors.
MYCN expression is associated with increased 
PARP expression and activity in NB cells
Colicchia et. al demonstrated that PARP1 and 
PARP2 expression are significantly associated with high-
risk NB and poor overall survival [25]. In addition, they 
demonstrated PARP protein levels are higher in MYCN 
expressing NB cell lines compared to non-expressing cells. 
Here, switching off MYCN in SHEP-Tet21/N cells was 
seen to slightly reduce expression of PARP1 protein and 
appeared to cause an associated reduction in endogenous 
PAR activity as indicated by western blotting (Figure 2C). 
In addition, the endogenous activity of PAR also differed 
when observed by immunofluorescent staining of PAR in 
MYCN ON and in MYCN-amplified IMR-32 cells (Figures 
1 and 2, and quantified in Figure 3A, Mann–Whitney U 
test p<0.01 when comparing both IMR-32 with SHEP-1 
and MYCN ON with MYCN OFF). Importantly, PARP 
activity was confirmed in MYCN-amplified IMR-32, non-
amplified SHEP-1, MYCN OFF and MYCN ON cells 
using a highly sensitive in vitro quantitative assay (Figure 
3B). Both MYCN-amplified and MYCN expressing cells 
displayed significantly higher levels of PARP activity than 
non-amplified/expressing cells (Student’s t-test p<0.001), 
confirming increased endogenous PARP activity is 
correlated to MYCN expression.
Expression of MYCN and/or inhibition of PARP 
induces DNA damage in NB
PARP plays multiple roles in repair of both double 
and single strand DNA breaks, and PARP inhibitors are 
generally considered to cause cell death by interfering with 
these functions. In order to examine the mechanism of PARP 
inhibitor mediated cell death in NB, levels of DNA damage 
were examined in the SHEP-Tet21/N MYCN ON and MYCN 
OFF cells in the presence and absence of the PARP inhibitor 
olaparib. Expression of MYCN alone resulted in a small but 
significantly increased level of DNA damage as visualised 
by immunofluorescent staining of γH2AX foci and 53BP-1 
foci (Figure 4 and Supplementary Figure 6, γH2AX mean 
foci/cell MYCN OFF = 4.28 c.f MYCN ON = 6.44, Mann–
Whitney U test p<0.01, 53-BP-1 mean foci/cell MYCN 
OFF = 3.51 c.f MYCN ON = 6.08, Mann–Whitney U test 
p<0.01). Inhibition of PARP increased the number of γH2AX 
foci/cell in both MYCN expressing and non-expressing 
cells consistent with increased levels of DNA damage, with 
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an approximate approximate 2-fold increase in mean foci/
cell in each case (Figure 4A, Mann–Whitney U test p<0.05 
and p<0.001, respectively). In addition, a similar increase 
in 53BP-1 foci was seen (Figure 4B, Mann–Whitney U test 
p<0.01 and p<0.001, respectively) indicative specifically of 
DNA double strand breaks. Together these data suggest that 
increased levels of DNA damage (most likely double strand 
breaks) may be the cause of olaparib induced cell death in 
NB, with higher cytotoxicity in MYCN expressing cells being 
the result of overall higher levels of DNA damage.
Figure 1: MYCN amplification influences sensitivity to PARP inhibition in a range of NB cell lines. (A) GI50s of PARP 
inhibitors olaparib and niraparib in NB cell lines. MYCN gene status, MYCN expression status and other common mutation status are 
shown. Highlighting indicates the cell lines with MYCN expression. (B) GI50 values plotted against cell lines grouped by MYCN status. 
Significance was calculated using Student’s t-test comparing MYCN expressing to non-expressing cell lines, for each PARP inhibitor: 
* = p<0.05. (C) Western blot showing MYCN expression in each of the cell lines used. (D) Olaparib, talazoparib and veliparib mediated 
inhibition of poly(ADP-ribose) (PAR) synthesis detected by immunofluorescence in IMR-32 and Shep-1 NB cell lines. Cells were pre-
treated for 16 hours with 10 nM talazoparib, 1 μM olaparib or 1 μM veliparib, PARP activity was then induced with H2O2. Representative 
images are shown, PAR (green), DAPI (blue). (E) Cell viability determined by MTT assay after 96 hour treatment with: (i) olaparib; 
(ii) veliparib; and (iii) talazoparib in Shep-1 and IMR-32 NB cell lines. Statistical significance was calculated using the Student’s t-test, 
comparing Shep-1 to IMR-32 cells at each dose. In each case mean and SEM of 2 independent repeats each representing 8 replica data 
points are shown. *,**,*** = p<0.05, p<0.01, and p<0.001, respectively.
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PARP inhibitor induced DNA damage in NB cells 
expressing MYCN is associated with S phase of 
the cell cycle
During the examination of γH2AX foci, it was noted 
that PARP inhibition or expression of MYCN resulted in a 
small but significant increase in the number of micronuclei 
(MN)/cell (Student’s t-test p<0.05 in each case). Moreover, 
the additional MN were uniformly labelled with γH2AX 
(Figure 4C and Supplementary Figure 7). The combination 
of MYCN expression and PARP inhibition led to a much 
larger four fold increase in MN compared to MYCN OFF 
Figure 2: MYCN expression influences sensitivity to PARP inhibition in NB cell lines. (A) Survival fraction of SHEP-
Tet21/N NB cell line with MYCN ON or OFF as measured by clonogenic survival assay 14 days post treatment with olaparib. Statistical 
significance was calculated using the Student’s t-test, comparing MYCN OFF and MYCN ON cells. Mean and standard deviation of 
3 independent repeats are shown. *** = p<0.001. (B) Olaparib mediated inhibition of poly(ADP-ribose) (PAR) synthesis as detected by 
immunofluorescence in MYCN OFF and ON cell lines. Cells were pre-treated for 16 hours with 1 μM olaparib, PARP activity was then 
induced with H2O2. Representative images are shown, PAR (green), DAPI (blue). (C) Western Blot for PAR, PARP1, MYCN and β-actin, 
in MYCN ON and OFF cells 16 h post treatment with olaparib. (D) Survival fraction of IMR-32 cells transfected with MYCN targeting 
siRNA prior to treatment with olaparib measured by clonogenic survival assay. Mean and standard deviation of 3 independent repeats 
are shown. Statistical significance was calculated using the Student’s t-test, at 2.5 μM olaparib, where * = p<0.05, ** = p<0.01. Protein 
expression of IMR-32 NB cells following siRNA transfection targeting MYCN is also shown. (E) LD50 values calculated from survival 
curves of SHEP-Tet21/N NB cell line with MYCN ON or OFF that were generated by clonogenic survival assay (above and Supplementary 
Figure 3) following exposure to the PARP inhibitors olaparib, talazoparib, and veliparib.
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DMSO control (Student’s t-test p<0.01,), approximately 
half of which were γH2AX labelled. Such foci have been 
reported as associated with DNA replication stress [34, 
35]. Further, PARP inhibition has been shown to increase 
DNA double strand breaks by inducing replication fork 
collapse during S-phase of the cell cycle [24]. In order 
to determine whether the increased DNA damage seen 
here is associated with any particular phase of the cell 
cycle, flow cytometry was used, co-staining for DNA 
with propidium iodide and DNA damage with a γH2AX 
antibody. In this assay, cells were classified as γH2AX foci 
positive or negative and the percentage of positive cells 
at each stage of the cell cycle determined (Figure 4D and 
Supplementary Figure 8); total cell cycle prolife (γH2AX 
positive plus and negative cells) is shown in Figure 4E. 
Consistent with γH2AX foci induction expression of 
MYCN or PARP inhibition significantly increased the 
total percentage of cells staining positive for γH2AX, 
with the largest γH2AX staining occurring in MYCN 
ON PARP inhibited cells (Student’s t-test p<0.05 in each 
case). Expression of MYCN resulted in an increase in 
the percentage of γH2AX positive cells, specifically in 
the G2/M phase of the cell cycle (Student’s t-test p<0.05, 
MYCN ON + DMSO c.f MYCN OFF + DMSO), likely 
reflective of the overall MYCN induced increase in G2/M 
phase cells. Addition of olaparib to MYCN OFF cells 
also resulted in an increase in percentage of γH2AX 
positive cells specifically in G2/M phase, although this 
was not statistically significant. No associated change in 
overall cell cycle profile was seen upon PARP inhibition. 
In MYCN ON cells, olaparib further increased the 
percentage of γH2AX positive cells. This increase was 
seen in S-phase (p<0.01, MYCN ON + DMSO c.f MYCN 
ON + olaparib) and G2/M phase cells, although again the 
increase in G2/M was not statistically significant. These 
data suggest that while MYCN or olaparib alone increase 
γH2AX in G2/M phase cells, only when they are combined 
can an increase in γH2AX in S-phase cells be detected.
MYCN slows replication fork progression 
and induces replication fork stalling which is 
exacerbated by olaparib treatment
It has previously been suggested that MYCN 
induces replication stress and that this makes cells 
sensitive to inhibition of PARP [25, 26, 36, 37]. Here, 
Figure 3: MYCN expression results in higher endogenous PARP activity in NB cell lines. IMR-32 (MYCN-amplified), 
SHEP-1 (MYCN non-amplified) and SHEP-Tet21/N with MYCN expression ON or OFF were used. (A) Quantification of PAR 
immunofluorescence staining in NB cell lines. A minimum of 100 cells were analysed and statistical significance between cell lines was 
calculated using the Mann–Whitney U test where ** represents p<0.01. (B) Quantification of PARP activity in NB cell lines as measured 
by the ability to add biotinylated PAR polymers onto histones, mean and standard deviation of triplicate repeats are shown. Statistical 
significance was calculated using the Student’s t-test, *** = p<0.001.
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the progression of single replication forks was directly 
examined using the DNA fibre assay (Figure 5A-D & 
Supplementary Figure 9). In this assay, expression of 
MYCN significantly reduced the mean replication fork 
speed by 25% (Mann–Whitney U p<0.001), and increased 
replication fork stalling 1.7-fold (Student’s t-test p<0.05). 
This is the first direct evidence that expression of MYCN 
causes replication fork stress in NB cells.
PARP1 is also reported as having a role at stalled 
replication forks where it both protects transiently stalled 
Figure 4: PARP inhibition induces more DNA damage and DNA double-strand breaks in NB cells when MYCN is 
expressed, predominantly in the S-phase of the cell cycle. (A) Number of γH2AX and (B) 53BP-1 foci/cell in SHEP-Tet21/N cells 
with MYCN ON and OFF 16 hours post treatment with 1 µM olaparib or DMSO control. Data shown are pooled from three independent 
repeats, for each repeat n>50 cells. Statistical significance was calculated using the Mann–Whitney U test. (C, left) Number of γ-H2AX 
positive and negative micronuclei (MN)/cell in MYCN ON and MYCN OFF cells 16 hours post treatment with 1 µM olaparib or DMSO 
control. Mean +/– SEM of three independent repeats are shown, where >50 cells were counted on each occasion; significance indicated is 
between total MN/cell. Statistical significance was calculated using the Student’s t-test. RIGHT: examples of γ-H2AX foci and γ-H2AX 
+ve and –ve MN (D) Percentage of total cell population γH2AX positive in each phase of cell cycle and (E) cell cycle profile of all cells 
regardless of γH2AX, 10 hours post treatment of MYCN OFF and MYCN ON cells with 1 µM olaparib or DMSO control. Data in (D) and 
(E) are the mean and SEM of 3 independent repeats each representing 10,000 cells, significance above the graph compares total γH2AX 
positive under each condition, indicated significances in table below are between γH2AX positive in each phases of the cell cycle and were 
calculated by Student’s t-test. Throughout significance is indicated *, **, *** = p<0.05, <0.01, and <0.001, respectively.
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forks from collapse [38] and mediates MRE11-dependent 
replication restart and homologous recombination at 
collapsed forks [23]. Consistent with this function, 
exposure to olaparib significantly increased stalling of 
replication forks regardless of MYCN status. The overall 
level of stalled forks was highest in MYCN-expressing 
PARP inhibited cells, with 36% of replication forks 
stalled in MYCN ON olaparib treated cells. Mean fork 
speeds were also reduced by olaparib in both MYCN ON 
and OFF cells. Interestingly, this was only statistically 
significant in MYCN ON cells (Mann–Whitney U test U 
p<0.05), suggesting that although olaparib is having similar 
effects on fork progression in the presence or absence of 
MYCN, the overall effect of PARP inhibition on replication 
is greater when NB cells express MYCN. Depletion of 
PARP1 in MYCN ON and OFF NB cells also increased 
fork stalling, further supporting a protective function for 
PARP during NB replication (Supplementary Figure 9).
Perturbed replication forks can be restarted by two 
independent RAD51 pathways dependent on the nature of 
the lesion induced [39, 40]. Examination of RAD51 foci 
revealed that MYCN expression significantly increased 
RAD51 foci formation (Figure 5E and Supplementary 
Figure 10, p<0.01). In MYCN ON cells olaparib did not 
increase this level further, suggesting that whilst DNA 
damage is increased in MYCN expressing PARP inhibited 
cells, there is no corresponding increase in RAD51 
mediated pathways for restart. It is likely that the overall 
effect on replication is sufficient to result in persistent DNA 
damage and therefore the increased PARP inhibitor induced 
toxicity seen in MYCN-amplified/expressing cells.
Increased levels of DNA damage and replication 
fork stalling are also seen in MYCN amplified 
cells upon inhibition of PARP
Increased PARP inhibitor induced cell killing was 
seen in both MYCN ON v.s MYCN OFF cell lines and in 
a panel of MYCN amplified cell lines compared to non-
amplified cells (Figure 1). Examination of γH2AX foci 
and DNA fibre analysis demonstrated that levels of DNA 
damage and replication fork stalling are also increased by 
PARP inhibition in the MYCN amplified neuroblastoma cell 
line IMR-32 (Supplementary Figure 11), suggesting that 
MYCN expression due to amplification also results in cell 
death due to effects on DNA fork stability and confirming 
that the findings in the MYCN ON/OFF expression system 
are conserved in MYCN amplified cells.
Olaparib inhibits growth of MYCN expressing 
tumours in vivo
Despite promising in vitro data, a previous in vivo 
study of PARP inhibition in MYCN amplified NB failed to 
demonstrate any significant benefit on tumour growth or 
survival [27]. To further validate whether olaparib treatment 
is feasible in the context of MYCN expression, olaparib 
trials were conducted in transgenic Th-MYCN mice [41]. 
Mice bearing MYCN expressing tumours were treated with 
50 mg/kg olaparib once daily and the long-term survival 
was assessed over the course of 8 weeks. Treatment with 
olaparib significantly prolonged the survival of animals 
(n=8) compared to vehicle-treated animals (n = 9) (Figure 
6A&B, log-rank p<0.05). Of the eight mice in the treatment 
group survival ranged from 7 to 57 days, while the control 
group range was 2–14 days. T2-weighted anatomical MRI 
demonstrated a marked tumour growth inhibition compared 
to vehicle controls (Figure 6C–6D (Supplementary Figure 
12), Student’s t-test p<0.01). This is considered a moderate 
and optimistic response compared to NB standard therapies 
tested in the same model [42]. Increased levels of γH2AX 
staining in tumours from olaparib treated compared to 
control animals support of the idea that olaparib is reducing 
tumour death through increased levels of unresolved DNA 
damage (Figure 6E). These data support the potential of 
PARP inhibition in MYCN expressing tumours. Finally 
the ability of PARP inhibition to sensitize NB cells to the 
chemotherapeutic agents temozolomide and camptothecin 
was tested (Figure 7). Olaparib was able to sensitize both 
MYCN expressing and non-expressing cells to both agents 
suggesting that combination therapies may be clinically 
beneficial in NB patients.
DISCUSSION
Our data support an emerging paradigm in which 
MYCN expression generates high levels of oncogenic 
replication stress in NB cells and that this can be exploited 
for therapeutic gain by inhibiting PARP.
It is well established that the Myc family of proteins 
induce replication stress and DNA damage leading to 
activation of the DDR [25, 43]. Utilising a DNA fibre 
assay we provide the first direct evidence of MYCN 
expression increasing replication stress in NB cells. 
MYCN expression resulted in slowed DNA replication 
and an increase in stalled replication forks. Fork stalling 
can be due to altered fork progression or changes in fork 
stability. Given that Myc proteins are thought to promote 
DNA replication it seems likely that MYCN alters fork 
progression either by promoting the cell cycle progression, 
by promoting transcription of related metabolic pathways 
and/or by directly regulating replication origin firing. 
The induction of RAD51 foci in the presence of MYCN 
could suggest the presence of uncoupled, remodelled 
replication forks occurring at sites of replication stress 
[44]. Alternatively given the concurrent increase in DNA 
double strand breaks seen, it is possible that the stalled 
forks represent sites of collapsed replication forks. Such 
collapsed replication forks are normally repaired by 
homologous recombination [23] and this may also account 
for the increased RAD51 foci seen in MYCN expressing 
cells.
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PARP1 and PARP2 have a complex relationship 
with DNA replication fork stalling/collapse. Both proteins 
are involved in single strand break repair (SSBR) [12], a 
lack of which can lead to increased collapsed replication 
forks [40]. In addition, they are themselves activated 
during replication stress. At hydroxyurea-induced 
transiently stalled forks, PARP1 serves to protect the fork 
from MRE11 mediated degradation [38, 39], while after 
Figure 5: MYCN expression perturbs replication forks in NB cells and this is exacerbated upon PARP inhibition. DNA 
fibre analysis of replication fork speed and stalling in olaparib treated SHEP-Tet21/N cells with MYCN ON and MYCN OFF cells. (A) Cells 
were incubated in 1 µM olaparib or DMSO control and then pulse labelled with CldU, for 20 min, and labelled switched to IdU for 20 min. (B) 
DNA fibre length (µm) and (C) Percentage fork stalling, calculated as a  percentage (%) of CIdU only labelled tracts (red) from continuous 
forks (CIdU (red) and IdU (green) labelled tracts). For (B and C) at least 100 forks were counted on each of three separate occasions, (B) 
shows pooled data (means of individual repeats is shown in Supplementary Figure 9), (C) shows means of 3 independent repeats. Statistical 
significance was calculated using the Mann–Whitney U test (pooled data) and Student’s t-test (means). (D) Example images of replication 
forks, an example of continuous (a) and stalled forks (b) are circled. (E) Number of RAD51 foci/cell in MYCN ON or MYCN OFF cells 16 
h post treatment with 1μM olaparib or DMSO control. Data are pooled from three independent repeats for each repeat n>50 cells. Statistical 
significance was calculated using the Mann–Whitney U test. Throughout *,**, and *** represent p<0.05, <0.01, and <0.001, respectively.
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prolonged stress with hydroxyurea, activated PARP1/2 
mediates effective restart of the stalled fork via promotion 
of homologous recombination [23]. Furthermore during 
various mild replication stresses PARP1 has been 
shown to play a role in regulation of replication restart 
at reversed replication forks [44]. Regardless of MYCN 
status, it seems probable both inhibition of SSBR and 
destabilisation of collapsed, stalled or reversed forks 
Figure 6: Olaparib significantly prolongs survival in the Th-MYCN mouse model of NB. (A) Kaplan-Meier survival analysis 
for Th-MYCN animals (9 in vehicle control group, 8 in treatment group) treated daily with 50 mg/kg olaparib as a single agent. Treated 
group versus control group, p = 0.0186 by log-rank test. (B) Survival data as above but presented in days where each bar represents an 
individual animal. (C) Waterfall plot documenting relative changes in tumour volume in the Th-MYCN mouse model following seven-day 
treatment with daily dose of 50 mg/kg olaparib, p = 0.0159 (Mann–Whitney U test with a 5% level of significance). (D) Representative day 
0 and 7 T2-weighted MRI abdominal sections of Th-MYCN mice treated daily with vehicle or with 50 mg/kg olaparib. Dashed white lines 
indicates tumour circumference. (E) Images of H&E and immunohistochemical staining for H2AX and γH2AX of Th-MYCN tumours.
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contribute to the increased levels of DNA damage seen 
after olaparib treatment. However, when MYCN is 
expressed and replication stress increased, PARP inhibition 
is likely to have a greater effect due to lack of repair and/
or protection of MYCN-induced perturbed forks. We 
therefore propose that when MYCN is expressed and 
PARP is inhibited, fork instability and DNA damage reach 
a critical point and cell death is induced. This explains 
increased sensitivity to PARP inhibition in NB cells 
expressing MYCN. The hypothesis is supported by the 
large number of replication associated MN and increase 
in S-phase associated γH2AX foci seen in olaparib treated 
MYCN expressing cells.
Interestingly, whilst RAD51 foci were increased in NB 
cells expressing MYCN, a further increase was not observed 
with olaparib treatment. Previous work has suggested that 
both remodelled fork restart during replication stress [44] 
and homologous recombination at stalled forks is reliant on 
PARP1 and PARP2 [23] and our data suggests this may be the 
case with MYCN-induced replication stress. However, the 
precise relationship between PARP, MYCN and replication 
fork dynamics requires further investigation.
Given its function as a transcription factor it seems 
probable that MYCN expression results in increased 
expression of DNA repair proteins to enable NB cells to 
cope with this replication stress. mRNA expression of the 
PARP family of proteins has been correlated with MYCN 
amplification prognosis in neuroblastoma [25] and here 
we provide in vitro evidence that PARP1 protein and PAR 
activity is increased in association with MYCN expression. 
In order to demonstrate a role for other key DDR proteins 
in MYCN-amplified NB gene expression data from a 
Figure 7: Inhibition of PARP sensitizes NB cells to camptothecin and temozolomide. Cell viability determined by MTT 
assay after 96 hours treatment with 0.5 μM olaparib and temozolomide (left) or camptothecin (right) in MYCN OFF (top) and MYCN ON 
(bottom) cells. Statistical significance was calculated using the Student’s t-test, comparing with and without olaparib at the highest dose 
used. In each case mean and SEM of 2 independent repeats each representing 8 replica data points are shown. *,**,*** = p<0.05, p<0.01, and 
p<0.001, respectively.
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published RNAseq [45] cohort was interrogated (498 
human NB samples). Increased expression of ATR, 
Chk1, Chk2, RAD51, BRCA1 and BRCA2 all predict 
a worse prognosis in NB and are significantly higher in 
cases with MYCN amplification (Supplementary Figure 
13). A transcriptional role for MYCN in upregulating 
the DDR has been given further credence by the recent 
identification of MYCN binding sites in the promoters of 
PARP1, PARP2, BRCA1, RMI2, and TOPBP1, albeit in 
castration resistant prostate cancer [46].
Recent reports have suggested that another subset 
of high-risk neuroblastoma with 11q deletion may also be 
sensitive to PARP inhibition. It has been suggested that 
this is probably due to a deficiency in HRR associated 
genes ATM, MRE11A, H2AFX, and CHEK1 [47–49]; such 
tumours very rarely have concurrent MYCN amplification. 
This raises the intriguing possibility that PARP inhibition 
may be effective in the two most common sub-groups of 
NB but for different reasons. In tumours with 11q deletion 
it is a specific defect in the DDR that renders sensitivity 
to PARP inhibition, exploiting the concept of synthetic 
lethality. In MYCN expressing disease it is likely a general 
over-reliance on the DDR due to oncogenic replication 
stress that leads to PARP inhibitor sensitivity.
Previous work has failed to reach a consensus 
concerning the potential of PARP inhibitors for use in 
NB [25–27] and only one recent report has specifically 
examined the effect of MYCN expression on efficacy 
and the association between replication stress and PARP 
inhibition [25]. Here, we demonstrate the efficacy of a 
range of PARP inhibitors in a number of NB cell lines 
and show this efficacy is related to MYCN expression. 
Further, we report for the first time that olaparib can be 
utilised to increase survival in a transgenic murine model 
of MYCN expressing NB. This model shows a moderate 
and optimistic response to monotherapy with the PARP 
inhibitor olaparib, although the effect is not comparable to 
standard therapies tested in the same model [42].
The majority of our data indicate that both MYCN 
expression and MYCN amplification are associated with 
PARP inhibitor sensitivity. MYCN amplification leads 
to the overexpression of MYCN at both the mRNA and 
protein levels [50] and ectopic expression of MYCN is 
often used in pre-clinical models of high-risk disease 
[33, 51]. However, the clinical significance of MYCN 
expression without MYCN amplification is uncertain, 
with some reports suggesting it confers an unfavourable 
prognosis [52] whilst paradoxically others suggest it is 
associated with better outcomes [53]. We evaluated the 
efficacy of olaparib in the TH-MYCN transgenic mouse 
model, which leads to high MYCN expression specifically 
in neural crest lineage cells, and is a widely used genetic 
model of high-risk neuroblastoma [54]. However, given 
MYCN expression is driven by the TH promoter rather 
than by genomic amplification it is not a true model of 
MYCN amplified neuroblastoma. Interestingly, a previous 
in vivo study used a MYCN-amplified cell line in a 
xenograft model and found a PARP inhibitor did not affect 
tumour growth [27]. Another limitation of our study is that 
we have not evaluated PARP inhibitors in cell line models 
of progressive disease, which have undergone intensive 
prior therapy exposure. Early phase clinical trials are likely 
to be heavily reliant on such cases. We therefore suggest 
further studies with additional in vitro and in vivo models 
of high-risk and progressive neuroblastoma are required 
before clinical testing of PARP inhibitors in children with 
neuroblastoma. It may also be that PARP inhibitors are 
more effective in combination with other DNA damaging 
agents, indeed our initial investigations show that olaparib 
can sensitize to both temozolomide and camptothecin, 
with a greater fold increase in sensitization being seen in 
MYCN expressing cells (Figure 7). The S-phase specific 
interaction between MYCN and PARP is likely to guide 
which agents will give the largest effects in high-risk NB, 
and will be the focus of future research.
In conclusion, we show that MYCN induces 
replication stress in NB cells and that this is exacerbated 
with pharmacological PARP inhibition leading to the 
selective killing of NB cells expressing MYCN. We 
also confirm the in-vivo feasibility of using olaparib in 
NB using a transgenic model of MYCN expressing NB. 
Together with other work showing the effectiveness of 
PARP inhibitors in NB tumours with 11q deletion, our 
findings provide evidence for a potential role for PARP 
inhibitors in the management of high-risk NB.
MATERIALS AND METHODS
Cell culture
Kelly, SH-SY5Y, SHEP-1, SK-N-SH, IMR-32, 
SKN-Be2C, IMR5 and SK-N-AS human neuroblastoma 
cell lines were obtained from the University of California 
at San Francisco Cell Culture Facility (San Francisco, CA, 
USA) and from the American Type Culture Collection 
(Manassas, VA, USA) and were routinely authenticated 
by STR-analysis (Institute of Cancer Research, Sutton, 
UK). Cell lines were used between 2 and 20 passages 
of original stocks. MYCN status and PARP activity was 
confirmed before and during the experiments. SHEP-
Tet21/N cells were a gift from Dr Deborah Tweddle 
(University of Newcastle, UK). SHEP-Tet21/N, SHEP-1 
and IMR-32 cells were also STR tested retrospectively 
at the end of the study by Culture Collections, Public 
Health England, Porton Down, UK. Cell lines were 
routinely tested for mycoplasma by PCR (Sigma MP0035 
LookOut® Mycoplasma PCR Detection Kit). All cell 
lines were grown at 37°C in an atmosphere containing 
5% CO2. IMR-32 cells were cultured in Dulbecco’s 
modified Eagle Medium (DMEM, Gibco, ThermoFisher 
Scientific, MA, USA) and RPMI-1640 Medium (Gibco, 
ThermoFisher Scientific, MA, USA) mixed in a 50:50 
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ratio and supplemented with 10% Foetal bovine serum 
(FBS, Gibco, ThermoFisher Scientific, MA, USA). 
SHEPTet21/N cells were grown in RPMI-1640 Medium 
supplemented with 10% tetracycline-free FBS (BioSera, 
UK). The SHEP-Tet21/N MYCN expression system was 
used as previously described to conditionally express 
MYCN in a non-MYCN-amplified background. MYCN 
expression was switched off by the addition of 1 µg/mL 
tetracycline 48 h prior experiments. All other cell lines 
were grown in DMEM supplemented with 10% FBS.
PARP Inhibitors
Olaparib was purchased from Cambridge Biosciences 
(UK) and veliparib, talazoparib and niraparib (MK4827) 
were purchased from Selleckchem (UK). All were dissolved 
in 100% DMSO to give a 10 mM stock. When confirming 
inhibition of PARP, PARP inhibitors were added overnight 
(16 h) for convenience. Temozolomide and camptothecin 
were purchased from Sigma-Aldrich (UK).
siRNA
IMR-32 cells were transfected with two unique 27-
mer siRNA duplexes against human MYCN (siMYCNA, 
ACGCUGAUACAUAACUAAAUUUGAA; siMYCNB, 
5-AGUUCAUACCUAAGUACUGUAAUAA-3; siMYCNC, 
5-AGCUGAUCCUCAAACGAUGCCUUCC-3.) and the 
control duplex (Trilencer-27 Universal Scrambled Negative 
Control siRNA Duplex) (Origene, UK). Cells were transfected 
with 20 nM siRNA (final concentration) using Lipofectamine 
RNAiMAX transfection reagent (Life Technologies, CA, 
USA) in accordance with the manufacturer’s instructions.
Calculation of GI50
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-metho 
xyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) 
assay (Promega, WI, USA) was performed according 
to the manufacturer’s instructions. Cells were seeded 
in 96-well plates 24 hr before treatment. Stock solution 
of olaparib and niraparib was prepared in 100% 
DMSO, serially diluted in growth media to a range of 
concentrations and added to the cells resulting in a final 
volume of 200 µL per well. After 72 hr at 37°C, warmed 
MTS solution were added to each well and further 
incubated for 2 hr at 37°C before the absorbance was 
measured. GI50 was calculated using GraphPad Prism 5.0 
(GraphPad software, CA, USA). Percentage survival was 
calculated as: % survival = (Abs treated – Abs blank)avg / 
(Abs control – Abs blank)avg × 100.
MTT assay
Cells were plated in 96-well plates 24 hours prior 
to addition of inhibitors. After 96 h at 37°C MTT solution 
was added and plates incubated for 3 hours before 
formazan precipitate was dissolved DMSO and optical 
density read (Thermo Scientific Multiskan FC microplate 
reader). Cell viability was calculated compared to 
untreated controls. For sensitization assays temozolomide 
or camptothecin were added 4 hours after olaparib.
Clonogenic survival assay
Cells were plated at known densities in 90 mm 
dishes. After 4 h PARP inhibitors were then added to 
the media. After 10–14 days colonies were stained 
with 4% methylene blue in 70% methanol and counted. 
In experiments using siRNA knockdown, cells were 
transfected in 6-well plates and left for 48 h before 
re-plating as above.
Western blotting
Cells were lysed in RIPA buffer (50 mM Tris-HCl, 
150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1 mM 
EDTA, and 1% sodium deoxycholate) in the presence of 
1× protease and phosphatase inhibitor cocktails (Sigma-
Aldrich, MO, USA). Proteins were resolved by SDS-
PAGE and transferred to Hybond ECL membrane (GE 
Healthcare, CO, USA). The membrane was immunoblotted 
with antibodies against Poly(ADP-ribose) 10H (ALX-804-
220-R100, 1:400, Enzo Life Sciences, NY, USA), PARP1 
(sc-8007, 1:1000, Santa Cruz Biotechnology, TX, USA), 
MYCN (sc-53993,1:250, Santa Cruz Biotechnology) and 
TUBB (T8328, β-tubulin; 1:5000, Sigma-Aldrich), each 
diluted in 5% milk and incubated at 4°C overnight. After the 
application of the appropriate HRP-conjugated secondary 
antibody and further washes, the immunoreactive protein 
was visualised using ECL reagents (GE Healthcare, IL, 
USA) according to the manufacturer’s instructions.
Immunofluorescence
Cells were plated on to coverslips and allowed to 
adhere for 4 hours prior to treatment as indicated. Cells 
were fixed in 4% paraformaldehyde solution (Insight 
Biotechnology Ltd, UK) for 20 min at room temperature 
and extensively washed (3 × 5 min in tris-buffered saline 
(TBS), 1 × 10 min in phosphate-buffered saline (PBS) 
containing 0.5% Triton X-100 and 3 × 5 min in TBS). 
Coverslips were placed in 3% bovine serum albumin 
(BSA, Sigma-Aldrich, MO, USA), in TBS for 1 hour at 
room temperature to block followed by a further 3 × 5 
min washes in TBS prior to incubation with the primary 
antibodies: anti-γH2AX (ser139) (#2577 Cell Signaling, 
MA, USA), RAD51 (sc-8349, Santa Cruz Biotechnology, 
TX, USA), Ki67 (ab15580, abcam, UK) or the PAR 
binding reagent MABE1016 (Millipore, MA, USA) (each 
diluted 1:500 in TBS containing 3% BSA for 16 hours 
at 4°C. The coverslips were subsequently washed 4 × 10 
min in TBS followed by incubation with the secondary 
antibodies, Alexa-fluor 594 goat anti-rabbit IgG or Alexa-
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fluor 488 goat anti-Mouse IgG (ThermoFisher Scientific, 
MA, USA) diluted in TBS containing 3% BSA (1:500) for 
1 hour at room temperature and finally washed 3 × 5 min 
TBS. The cells were washed 3 times in PBS with 1/1000 
DAPI applied for the last wash. Finally, the coverslips 
were mounted on to microscope slides using Vectashield 
(Vector Laboratories, UK).
All images were obtained with a Zeiss LSM 510 
inverted confocal microscope using a planapochromat 
63×/NA 1.4 oil immersion objective and excitation 
wavelengths 488 nm, 546 nm, and 630 nm. Through focus 
maximum projection, images were acquired from optical 
sections 0.5 µM apart and with a section thickness of 1.0 
µm. The frequency of cells containing foci was determined 
by counting at least 100 nuclei on each independent repeat. 
Images were processed for publication using the ImageJ 
NIH image processing software. The number of foci from 
at least 50 cells in each of three independent experiments 
was counted.
Micronuclei scoring
Immunofluorescence for γH2AX was performed 
on cells as detailed above. Imaging was again performed 
using a Zeiss LSM 510 inverted confocal microscope and 
planapochromat 63×/NA 1.4 oil immersion objective. 
Micronuclei (MN) were first identified using DAPI 
staining. MN were then examined for the presence or 
absence of γ-H2AX signal. A MN was designated as MN-
γ-H2AX (+) if it was uniformly stained with γ-H2AX. 
MN were scored as either negative or positive for γH2AX 
staining and the average number of micronuclei of either 
type was calculated from the total number of cells counted. 
Cells with three or more MN were not included to avoid 
possible artefacts due to catastrophic cellular events. MN 
from three independent experiments were counted.
γ-H2AX and cell cycle analysis
Cells were seeded in 90 mm dishes and left to attach 
overnight prior to treatment as indicated. Cells were then 
fixed in 70% methanol and stored overnight at –20°C. 
After washing in PBS, cells were resuspended in 2mLs 
PBS supplemented with 0.5% BSA (Sigma-Aldrich) and 
0.25% Triton-X100. Following 15 min incubation on ice, 
cells were resuspended with the antibody, anti-γH2AX 
[(ser139) (#2577 Cell Signaling, MA, USA), 1:50] diluted 
in 50 µL of PBS supplemented with 0.5% BSA and 0.25% 
Triton-X100 and incubated for 2 hours. Cells were then 
washed with 0.25% Triton-X100 in PBS and incubated with 
the secondary antibody Alexfluor 488 goat anti-rabbit IgG 
(1:500, diluted in 100 µL PBS supplemented with 1% BSA) 
for 30 min protected from light. Following a final wash with 
PBS, cells were incubated with 5 µL RNaseA (2 mg/mL) 
and 200 µL propidium iodide (PI, 50 µg/mL) for 15 minutes 
in the dark. Samples were analysed by flow cytometry using 
the FACSCalibur 488 nm laser (BD Biosciences, CA, USA) 
and more than 10000 cells were counted. All experiments 
were repeated three times. Data were analysed using 
FLOJO software (Tree Star, San Carlos, CA, USA).
DNA fibre analysis
Cells were seeded in a six well plate and left to attach 
for at least four hours prior to olaparib treatment overnight. 
The next day, chlorodeoxyuridine (CldU, Sigma-Aldrich, 
MO, USA) was added to the media to a final concentration 
of 25 µM and the cells were incubated for 20 minutes. 
5-iodo-2′-deoxyuridine (IdU, Sigma-Aldrich, MO, USA) 
was then added to media to a final concentration of 250 
µM for 20 minutes before washing with PBS. Cells were 
collected using trypsin and resuspended in cold PBS to 
a final volume of 4 × 105 cells/mL. 2 µL of cells were 
mixed with 7 µL of spreading buffer (200 mM Tris-HCl, 
pH 7.4, 50 mM EDTA, and 0.5% SDS) on a glass slide. 
After incubation for 2 minutes, the slides were tilted 
15–45° to allow the DNA spreads to run down the slide 
taking 3–5 minutes to reach the bottom edge. The DNA 
spreads were then air dried, fixed in 3:1 methanol/acetic 
acid, and refrigerated overnight. The next day, the DNA 
fibres were denatured in 2.5 M HCl for 1 h, washed with 
PBS, and blocked with 1% BSA in PBS-T (PBS and 0.1% 
Tween 20) for 1 hour. The newly replicated CldU and IdU 
tracks were labelled for 1 hour with the primary antibodies 
(1:1000 rat anti-BrdU antibody [BU1/75 (ICR1)] (ab6326, 
abcam, UK) and 1:750 mouse α-BrdU (Clone: B44, 
#347580 BD Biosciences, UK). After rinsing with PBS 3 
times, secondary antibodies were applied (α-rat AlexaFluor 
555 and α-mouse AlexaFluor 488, both at 1:500). After 
further washing with PBS, coverslips were applied using 
Vectashield (Vector Laboratories, UK) and after drying 
slides were stored at –20°C. The DNA fibres were 
visualised using an Olympus FV1000 confocal microscope 
with a PLAPON 60× oil objective lens. Lasers of 488 and 
542 nm wavelength were used to visualise AlexaFluor 488 
and AlexaFluor 555, respectively. Analysis was performed 
using the ImageJ NIH image processing software.
PARP enzyme assay
Endogenous PARP-1 enzyme activity in IMR-32, 
SHEP-1 and Sheptet21N cells with MYCN ON or OFF 
was determined using PARP/Apoptosis Colorimetric 
Assay Kit (Trevigen, MD, USA) following manufacturer’s 
instructions. In each case PARP activity was measured in 
500 cells. The results are presented as Units PARP/500 
cells in artificial units.
In vivo trial with Th-MYCN mice
All experimental protocols were monitored and 
approved by The Institute of Cancer Research Animal 
Welfare and Ethical Review Body, in compliance with 
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guidelines specified by the U.K. Home Office Animals 
(Scientific Procedures) Act 1986, the United Kingdom 
National Cancer Research Institute guidelines for the 
welfare of animals in cancer research [55], and the 
ARRIVE guidelines [56]. Transgenic Th-MYCN mice 
were genotyped to detect the presence of human MYCN 
transgene [41]. Mice were housed in specific pathogen-
free rooms in autoclaved, aseptic microisolator cages with 
a maximum of 4 animals per cage. Mice were allowed 
access to sterile food and water ad libitum.
Th-MYCN mice were treated with olaparib. Olaparib 
(50 mg/mL in 100% DMSO) was solubilized  and frozen 
at –20°C. On the day of treatment, the solution was 
thawed and diluted in 10% (w/v) 2-Hydroxypropyl)-
β-cyclodextrin (HBC; Sigma, Ayrshire, UK) in PBS. 
Tumour development was monitored weekly by palpation 
by an experienced animal technician. Mice with palpable 
tumours were then allocated into 2 treatment groups: 
olaparib-treated and vehicle controls (8–9 mice per 
group), unequal numbers were regrettably due to the 
poor penetrance (~11%) and long latency (mice develop 
tumours at 55–160 days with a mean age of 79 days at the 
time of enrolment) in the TH-MYCN heterozygous animal, 
9 animals were kept in the control group for sensitivity and 
precision. This number was determined to be high enough 
for statistical power. Olaparib was dosed by intraperitoneal 
(i.p.) injection once daily for 4 weeks. Tumour growth 
was monitored, as previously described [42], using T2-
weighted magnetic resonance imaging (MRI) on a 7T 
MicroImaging system (Bruker Instruments, Ettlingen, 
Germany) performed on days 0 and 7. The mean tumours 
volume between the vehicle- and olaparib treated cohorts 
were not statistically different at the time of enrolment 
(1391 ± 212 mm3 vs 1167 ± 158 mm3, mean ± 1 s.e.m, 
p = 0.4) For mice that had to be sacrificed/died before/
on day 7 and when imaging could not be performed, only 
survival data is presented. Individual group comparisons 
were performed using Student’s independent t-test and 
data were reported as significant where P<0.05.
Group sizes were determined power analyses 
using data from previous publications. A cohort size 
of 8 mice was chosen for this study with >30% effect 
size, 5% significance level using non parametric test 
and a minimum power of 95%, (minimum size = 4). No 
randomization was done due to the poor penetration and 
long latency of the model. Mice were assigned to either 
vehicle control or treatment in turn when a tumour was 
identified by palpation
Immunohistochemistry staining of fixed tissues
Animal tumours were harvested at sacrifice, fixed in 
10% (v/v) neutral buffered formalin, and paraffin-embedded 
for histologic studies. Four μm sections of paraffin-
embedded tumours were cut using a Leica microtome 
RM2235. The tissue sections were deparaffinised and 
rehydrated in water prior to antigen retrieval using 1% 
(v/v) citric acid for 23 min in a microwave (3 min at full 
power and additional 20 min at 40% of power), followed 
by a 25 min wash in 1% (w/v) hydrogen peroxide 
(Hydrogen peroxide 30% (w/v) aqueous solution AnalaR 
NORMAPUR®, VWR, Lutterworth, UK). VECTOR® 
M.O.M.™ immunodetection kit BASIC (Vector 
Laboratories, Peterborough, UK) was used. Non-specific 
antibody reactivity was blocked by incubation with M.O.M. 
IgG block containing 0.1% (v/v) Triton X-100 (Sigma, 
Ayrshire, UK) for mouse- or rat-derived antibodies or 
with 10% (v/v) BSA containing 0.1% (v/v) Triton X-100 
for all other species for 90 min at room temperature (RT). 
The sections were then incubated overnight at RT using the 
following antibodies (mouse-derived antibodies in M.O.M. 
diluents, rabbit antibodies in 0.1% BSA) and dilutions: 
γH2AX (1:500; (#2577, Cell Signaling Technology, MA, 
USA) and H2AX (1:100; #2572, Cell Signaling Technology, 
MA, USA).
Sections were incubated for 10 min at RT with 
biotinylated anti-mouse antibody (1:250 in M.O.M. 
diluent) or biotinylated anti-rabbit antibody (1:500 
in 0.1% BSA) followed by NeutrAvidin peroxidase 
(1:1000 from 1 mg/ml stock) incubation for 2 hr at RT. 
Detection was performed using ImmPACT DAB (Vector 
Laboratories, Peterborough, UK). For negative controls, 
the primary antibody was replaced by BSA. Slides 
were counterstained with haematoxylin and mounted/
coverslips with Histolab Pertex® (Algol Diagnostics, 
Finland).
Statistical analysis
Results were determined to be normally distributed 
or not using Shapiro-Wilk test for normality, prior to 
analysis with a paired Student’s t-test or a Mann–Whitney 
U test as relevant and indicated. p values below 0.05 were 
considered representative of data that were significantly 
different. Graphpad Prism 7 software was used for 
analysis of all data.
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